About Lundbeck
Lundbeck is a global pharmaceutical company conducting research into developing, manufacturing, marketing, selling and distributing pharmaceuticals for the treatment of disorders of the central nervous system (CNS), including depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington's disease, epilepsy and insomnia.
Central Nervous System Disorders
According to the World Health Organization (WHO) more than 700 million cases of central nervous system disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of patients as well as of their relatives.
As these diseases also involve major socio-economic costs, it is imperative for society as a whole that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionized treatment options, but there is still a great unmet need for new and innovative therapeutics.
Research and development
Lundbeck is one of Denmark’s most research-intensive enterprises. We employ 1,400 highly trained specialists in our research and development units. Each year, Lundbeck gives back about 20% of its revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from central nervous system disorders.
Products
Lundbeck markets a number of different pharmaceuticals for the treatment of disorders of the central nervous system (CNS).
Key figures
Lundbeck employs 5,900 people worldwide, 2,000 of whom are based in Denmark. We have employees in 57 countries, and our products are registered in more than 100 countries. We have production facilities in Italy, France, Mexico and Denmark and research centres in Denmark and the USA. Lundbeck generated revenue of approximately DKK 14.8 billion in 2010.
Management
Lundbeck’s overall management consists of our Executive Management (four members) headed by Ulf Wiinberg, President and CEO.
Market data
In 2010, 53% of our revenue derived from Europe, 25% from the USA and 20% from the International Markets region.
History
Lundbeck was founded by Hans Lundbeck as a trading company in 1915. Since then the company has evolved and grown dramatically. Today we are among the biggest Danish companies.
Ownership
In 1999, Lundbeck’s shares were listed on the Copenhagen Stock Exchange. The Lundbeck Foundation, which distributes more than DKK 300 million in grants for various types of research each year, owns about 70% of the shares in Lundbeck, while the remaining 30% are traded on the stock exchange.
To learn more about Lundbeck, visit www.lundbeck.com.
CNS Products in the U.S.
Pipeline
By clicking below you will be transferred from the Lundbeck website in the U.S. to the
H. Lundbeck A/S headquarters website. Some of the products and compounds displayed on the pipeline page have not been approved by the FDA as being safe or effective for the use under study. The information provided is for general information only and is not intended to provide medical advice or guidance and should not be used for that purpose. In the United States, a drug is not considered safe or effective for its intended use unless approved by the FDA.